Med-Tech Startup CytoVale Raises $7.4 Million

Want to share this story?

A startup can do a lot with $7.4 million, and San Francisco based Cytovale got that funding as part of a Series B extension.

The startup announced it has raised that amount from Breakout Ventures and Blackhorn Ventures, both lead investors. Western Technology Investment also joined the funding round.

In addition to this new funding, CytoVale announced it has entered into a partnership with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Division of Research, Innovation and Ventures. This partnership is valued at $7.6 million, bringing its cumulative funding haul to $15 million.

The funds will be used to advance the startup’s technology through Good Manufacturing Practice and conduct clinical studies needed to pursue regulatory clearance of the Cytovale test. The company’s core function is discovering revolutionary diagnostics using cell mechanics and machine learning, and applying this to sepsis, a very serious medical condition whose early detection dramatically improves patient outcomes.